The effects of orally ingested Delta-9-Tetrahydrocannabinol on drivers' hazard perception and risk-taking behaviours: A within-subjects study of medicinal cannabis users.
Taren Mieran, Andrew Hill, Mark S Horswill, Mathew J Summers, Kayla B Stefanidis
{"title":"The effects of orally ingested Delta-9-Tetrahydrocannabinol on drivers' hazard perception and risk-taking behaviours: A within-subjects study of medicinal cannabis users.","authors":"Taren Mieran, Andrew Hill, Mark S Horswill, Mathew J Summers, Kayla B Stefanidis","doi":"10.1007/s00213-025-06869-w","DOIUrl":null,"url":null,"abstract":"<p><p>Medicinal cannabis use is increasing worldwide, yet its impacts on driving safety in frequent users are not clearly understood. A more comprehensive understanding of the effects of THC on driving behaviour in frequent users is needed to guide drug driving policy and evidence-based advice for medicinal cannabis consumers. This study investigated the acute effects of orally ingested THC oil on medicinal cannabis users': (a) hazard perception skill performance; (b) driving-related risk-taking behaviours (speeding propensity, following distance, gap acceptance); (c) self-perceived hazard perception skill performance; and (d) self-perceptions of driving skills and safety. A within-subjects design was used to compare scores on validated video-based measures of hazard perception skill and risk-taking behaviours, along with self-report measures, between baseline (no THC) and post-consumption. Although participants' (N = 41) actual hazard perception skill performance did not significantly decline from baseline to post-consumption, their perceived performance did (with no significant correlation between the two in either condition). In the other video-based measures, participants selected significantly slower speeds and longer following distances post-consumption (but gap acceptance behaviour was unchanged). There was no significant change in self-perceptions of driving skills and safety after correction for multiple tests. While there was no evidence that oral ingestion of THC oils by medicinal cannabis users impacted hazard perception skill performance, they were unable to accurately self-assess their performance, regardless of whether they had consumed THC. Further, medicinal cannabis patients engage in compensatory strategies, specifically by reducing their speed and increasing their following distance following the consumption of THC.</p>","PeriodicalId":20783,"journal":{"name":"Psychopharmacology","volume":" ","pages":""},"PeriodicalIF":3.3000,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Psychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00213-025-06869-w","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 0
Abstract
Medicinal cannabis use is increasing worldwide, yet its impacts on driving safety in frequent users are not clearly understood. A more comprehensive understanding of the effects of THC on driving behaviour in frequent users is needed to guide drug driving policy and evidence-based advice for medicinal cannabis consumers. This study investigated the acute effects of orally ingested THC oil on medicinal cannabis users': (a) hazard perception skill performance; (b) driving-related risk-taking behaviours (speeding propensity, following distance, gap acceptance); (c) self-perceived hazard perception skill performance; and (d) self-perceptions of driving skills and safety. A within-subjects design was used to compare scores on validated video-based measures of hazard perception skill and risk-taking behaviours, along with self-report measures, between baseline (no THC) and post-consumption. Although participants' (N = 41) actual hazard perception skill performance did not significantly decline from baseline to post-consumption, their perceived performance did (with no significant correlation between the two in either condition). In the other video-based measures, participants selected significantly slower speeds and longer following distances post-consumption (but gap acceptance behaviour was unchanged). There was no significant change in self-perceptions of driving skills and safety after correction for multiple tests. While there was no evidence that oral ingestion of THC oils by medicinal cannabis users impacted hazard perception skill performance, they were unable to accurately self-assess their performance, regardless of whether they had consumed THC. Further, medicinal cannabis patients engage in compensatory strategies, specifically by reducing their speed and increasing their following distance following the consumption of THC.
期刊介绍:
Official Journal of the European Behavioural Pharmacology Society (EBPS)
Psychopharmacology is an international journal that covers the broad topic of elucidating mechanisms by which drugs affect behavior. The scope of the journal encompasses the following fields:
Human Psychopharmacology: Experimental
This section includes manuscripts describing the effects of drugs on mood, behavior, cognition and physiology in humans. The journal encourages submissions that involve brain imaging, genetics, neuroendocrinology, and developmental topics. Usually manuscripts in this section describe studies conducted under controlled conditions, but occasionally descriptive or observational studies are also considered.
Human Psychopharmacology: Clinical and Translational
This section comprises studies addressing the broad intersection of drugs and psychiatric illness. This includes not only clinical trials and studies of drug usage and metabolism, drug surveillance, and pharmacoepidemiology, but also work utilizing the entire range of clinically relevant methodologies, including neuroimaging, pharmacogenetics, cognitive science, biomarkers, and others. Work directed toward the translation of preclinical to clinical knowledge is especially encouraged. The key feature of submissions to this section is that they involve a focus on clinical aspects.
Preclinical psychopharmacology: Behavioral and Neural
This section considers reports on the effects of compounds with defined chemical structures on any aspect of behavior, in particular when correlated with neurochemical effects, in species other than humans. Manuscripts containing neuroscientific techniques in combination with behavior are welcome. We encourage reports of studies that provide insight into the mechanisms of drug action, at the behavioral and molecular levels.
Preclinical Psychopharmacology: Translational
This section considers manuscripts that enhance the confidence in a central mechanism that could be of therapeutic value for psychiatric or neurological patients, using disease-relevant preclinical models and tests, or that report on preclinical manipulations and challenges that have the potential to be translated to the clinic. Studies aiming at the refinement of preclinical models based upon clinical findings (back-translation) will also be considered. The journal particularly encourages submissions that integrate measures of target tissue exposure, activity on the molecular target and/or modulation of the targeted biochemical pathways.
Preclinical Psychopharmacology: Molecular, Genetic and Epigenetic
This section focuses on the molecular and cellular actions of neuropharmacological agents / drugs, and the identification / validation of drug targets affecting the CNS in health and disease. We particularly encourage studies that provide insight into the mechanisms of drug action at the molecular level. Manuscripts containing evidence for genetic or epigenetic effects on neurochemistry or behavior are welcome.